GNPX - Genprex, Inc.
| Previous Close | 1.8001 |
| Open | 1.8142 |
| Bid | 1.7900 x 2900 |
| Ask | 1.8900 x 1300 |
| Day's Range | 1.8142 - 1.8142 |
| 52 Week Range | 0.9500 - 19.4500 |
| Volume | 491 |
| Avg. Volume | 47,130 |
| Market Cap | 27.345M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7470 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.25 |
- GlobeNewswire•3 days ago
Genprex Inc. Discusses Plans to Expand Clinical Trials in Fight Against Cancer in Exclusive Audio Interview with NetworkNewsWire
NEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with Genprex Inc., a clinical stage gene therapy company developing a new approach to treating cancer. NNW’s Stuart Smith introduces Genprex CEO and Chairman Rodney Varner, JD, for a compelling discussion on the company’s initial product candidate, Oncoprex(TM), an immunogene therapy for non-small cell lung cancer (NSCLC). The American Cancer Society reports that NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancer.
- Newsfile•7 days ago
NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.'s Transformative Work in Gene Therapy
New York, New York--(Newsfile Corp. - March 15, 2019) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Making Profits, Saving Lives with Gene Therapy," featuring Genprex Inc. (NASD: GNPX).To hear the NetworkNewsAudio version, visit: http://nnw.fm/bw1cXTo read the full editorial, visit: http://nnw.fm/Y0ZqHThis evidence of the faith of the markets has helped boost stock values for a range of gene therapy companies, with some seeing triple digit growth. But these companies don't need to be the ...
- GlobeNewswire•7 days ago
NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.’s Innovative Approach to Gene Therapy
NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “Making Profits, Saving Lives with Gene Therapy,” featuring Genprex Inc. (GNPX). Delivery systems for the genes are as important as the genes themselves. Carriers called vectors deliver the genetic material into the cells.
- Business Wire•8 days ago
Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019.
- GlobeNewswire•8 days ago
NetworkNewsWire Announces Publication on Gene Therapy’s Promise for Improving Patient Treatments and Market Profitability
NEW YORK, March 14, 2019 -- via NetworkWire — NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial.
- GuruFocus.com•9 days ago
5 Biotech Stocks to Keep an Eye on in 2019
The biotech sector is an interesting one to follow. Warning! GuruFocus has detected 2 Warning Sign with CELG. There has been quite a bit of chatter recently surrounding the potential acquisition of the company by Bristol-Myers Squibb (BMY).
- Business Wire•23 days ago
Genprex Strengthens Senior Team and Continues to Advance Operations
Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform announced that it is continuing to grow its senior team with the hiring of Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing, effective immediately.
- Business Wire•last month
Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors
Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of John N. Bonfiglio, PhD, to the company’s Board of Directors. In recent years, Dr. Bonfiglio served as President and CEO of Oragenics, Inc. and most recently as President and COO of TapImmune, Inc., where he helped lay the groundwork for a successful merger with Marker Therapeutics, Inc. in October 2018 by up-listing TapImmune to Nasdaq and starting a robust clinical program in breast and ovarian cancers.
- Business Wire•2 months ago
Genprex to Present at NobleConXV in Fort Lauderdale, Florida
Genprex, Inc. (GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that its President and Chief Operating Officer, Julien Pham, MD, MPH, will deliver a presentation about the company’s unique, leading-edge gene therapies and will also participate in a discussion panel on the topic of “Novel Therapies at the Cutting Edge of Cancer Research” at NobleConXV - Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel in Fort Lauderdale, Florida.
- Business Wire•3 months ago
Genprex to Present at Biotech Showcase™ 2019 in San Francisco
Genprex, Inc. (GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare finance at the Hilton San Francisco Union Square. Genprex is pioneering a new approach to treating cancer–based upon a novel proprietary technology platform–that includes the company’s initial product candidate, Oncoprex™ immunogene therapy.
- Simply Wall St.•3 months ago
Are Insiders Buying Genprex, Inc. (NASDAQ:GNPX) Stock?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...
- Business Wire•3 months ago
Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019
Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be increasing its investor relations efforts in 2019, spearheaded by the launch of an innovative corporate website with more robust investor resources, including the company’s presentations, stock charts and integrated quotes, SEC filings, news, media coverage, and tailored email newsletters, among other advanced communication tools. As part of today’s announcement, investors already have the ability to receive all news regarding Genprex straight to their inbox by signing up for the company’s communication list at https://www.genprex.com/investors/email-alerts/.
- Business Wire•4 months ago
Genprex to Present at the 11th Annual LD Micro Main Event
Presentation Wed., Dec. 5, 2018, at 10:30 a.m. PST
- Business Wire•4 months ago
Genprex Provides Clinical and Corporate Update for Third Quarter 2018
Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update, and the filing of quarterly results for the third quarter ended September 30, 2018 on Form 10-Q with the Securities and Exchange Commission. Rodney Varner, Chairman and CEO, remarked, “Over the past quarter, we have taken steps to advance our clinical development activities.
- Business Wire•5 months ago
Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations
Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Jan Stevens, RN, as the Company’s Vice President of Clinical Operations. In this role, Ms. Stevens joins the Cambridge office to contribute in supporting various clinical development programs for the Company’s immunogene therapy, Oncoprex™, which is currently being evaluated in clinical and preclinical studies at MD Anderson Cancer Center for the treatment of non-small cell lung cancer (NSCLC).
- Business Wire•6 months ago
Genprex to Present at Upcoming Investor and Industry Conferences
Genprex, Inc. , a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today
- Business Wire•6 months ago
Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program
Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has signed an agreement with Aldevron, a leading contract manufacturing organization, to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprex’s clinical development program evaluating its immunogene therapy Oncoprex™ for the treatment of non-small cell lung cancer.
- Business Wire•7 months ago
Genprex to Present at Upcoming Investor Conferences
Genprex, Inc. , a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today
- Business Wire•7 months ago
Genprex Provides Clinical and Corporate Update for Second Quarter 2018
Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update, and the filing of quarterly results for the second quarter ended June 30, 2018 on Form 10-Q with the Securities and Exchange Commission. Rodney Varner, Chairman and CEO, remarked, “We have made significant progress in recent months to advance the development of Oncoprex™ for treatment of non-small cell lung cancer (NSCLC), including engaging collaborators with expertise and other resources necessary for important pre-clinical and clinical services.
- Business Wire•8 months ago
Genprex Updates Agreement with University of Texas MD Anderson Cancer Center to Resume Patient Enrollment in Phase I/II Study Evaluating Oncoprex/Erlotinib Combination Therapy in Non-Small Cell Lung Cancer
Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it has amended its agreement with The University of Texas MD Anderson Cancer Center to resume patient enrollment in its Phase I/II clinical trial evaluating the combination of the company’s investigational drug Oncoprex™ and erlotinib (Tarceva®) for the treatment of Stage IV non-small cell lung cancer (NSCLC). Oncoprex is a TUSC2 gene encapsulated in a positively charged nanovesicle made from lipid molecules and injected intravenously, which can specifically target cancer cells and insert wild-type TUSC2 into cellular DNA, effectively increasing expression of the TUSC2 protein and promoting tumor cell death.
- Business Wire•8 months ago
Genprex Enters Agreement with the University of Texas MD Anderson Cancer Center to Study Oncoprex in Combination with Immunotherapies
Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has entered a Sponsored Research Agreement (“Agreement”) with The University of Texas MD Anderson Cancer Center under which Genprex will sponsor a pre-clinical study, entitled “A Novel Therapeutic Approach for the Treatment of Cancer Using a Combination of the Multifactorial Tumor Suppressor Gene TUSC2 and Immunotherapy,” to be conducted under the direction of Jack A. Roth, MD, FACS. TUSC2 is the active agent in Genprex’s investigational drug candidate Oncoprex™.
- PR Newswire•8 months ago
Genprex To Present At The Singular Research Summer Solstice 2018 Conference
NEW YORK , July 18, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, ...
- PR Newswire•9 months ago
Genprex Selects 4Clinics To Provide Clinical And Regulatory Support For Oncoprex Development Program
AUSTIN, Texas AND CAMBRIDGE, Mass., June 26, 2018 /PRNewswire/ -- Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has selected 4Clinics Group Sprl to provide support for the clinical development of the Company's lead drug candidate, Oncoprex™, for the treatment of non-small cell lung cancer (NSCLC). "This is an important step forward for Genprex as we expand the scope of the Oncoprex clinical development program to build on the encouraging data we've compiled to date," said Julien Pham, MD, MPH, President and Chief Operating Officer of Genprex. 4Clinics is a global contract research organization that provides comprehensive clinical expertise to clients across data management, biostatistics, statistical programming, scientific writing, regulatory affairs and clinical operations services for clinical, observational and epidemiological studies.
- PR Newswire•10 months ago
Genprex Engages WIRB-Copernicus Group, Inc. To Provide Clinical Trial Services To Support Oncoprex Clinical Trial Program
AUSTIN, Texas, May 31, 2018 /PRNewswire/ -- Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it entered into a Master Services Agreement with WIRB-Copernicus Group, Inc. ("WCG"), through which WCG will serve as the Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) of record for new clinical trial sites that Genprex anticipates adding to participate in its Phase I/II clinical trial of lead product candidate, OncoprexTM, in combination with erlotinib (Tarceva®) in non-small cell lung cancer.
